MetLife Investment Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.5M | Sell |
339,986
-17,908
| -5% | -$972K | 0.07% | 285 |
|
|
2026
Q1 | $22.5M | Sell |
357,894
-9,647
| -3% | -$772K | 0.11% | 141 |
|
|
2025
Q4 | $35M | Sell |
367,541
-12,062
| -3% | -$1.18M | 0.17% | 84 |
|
|
2025
Q3 | $37.1M | Sell |
379,603
-8,890
| -2% | -$921K | 0.18% | 81 |
|
|
2025
Q2 | $41.7M | Buy |
388,493
+5,777
| +2% | +$585K | 0.25% | 58 |
|
|
2025
Q1 | $38.6M | Sell |
382,716
-7,296
| -2% | -$735K | 0.21% | 68 |
|
|
2024
Q4 | $34.8M | Buy |
390,012
+7,152
| +2% | +$630K | 0.19% | 83 |
|
|
2024
Q3 | $32.1M | Sell |
382,860
-9,262
| -2% | -$730K | 0.18% | 86 |
|
|
2024
Q2 | $30.2M | Buy |
392,122
+49,142
| +14% | +$3.6M | 0.18% | 88 |
|
|
2024
Q1 | $23.5M | Sell |
342,980
-12,446
| -4% | -$800K | 0.16% | 108 |
|
|
2023
Q4 | $20.5M | Sell |
355,426
-6,185
| -2% | -$330K | 0.15% | 110 |
|
|
2023
Q3 | $19.1M | Sell |
361,611
-3,270
| -0.9% | -$171K | 0.15% | 109 |
|
|
2023
Q2 | $19.7M | Sell |
364,881
-4,656
| -1% | -$243K | 0.14% | 114 |
|
|
2023
Q1 | $18.5M | Sell |
369,537
-4,428
| -1% | -$209K | 0.13% | 117 |
|
|
2022
Q4 | $17.3M | Sell |
373,965
-5,954
| -2% | -$258K | 0.13% | 125 |
|
|
2022
Q3 | $14.7M | Sell |
379,919
-5,157
| -1% | -$207K | 0.12% | 136 |
|
|
2022
Q2 | $14.4M | Sell |
385,076
-2,534
| -0.7% | -$103K | 0.11% | 144 |
|
|
2022
Q1 | $17.2M | Buy |
387,610
+72,770
| +23% | +$3.15M | 0.11% | 146 |
|
|
2021
Q4 | $13.4M | Sell |
314,840
-6,752
| -2% | -$284K | 0.11% | 146 |
|
|
2021
Q3 | $14M | Sell |
321,592
-7,840
| -2% | -$347K | 0.13% | 135 |
|
|
2021
Q2 | $14.1M | Sell |
329,432
-8,277
| -2% | -$348K | 0.12% | 136 |
|
|
2021
Q1 | $13.1M | Sell |
337,709
-10,041
| -3% | -$380K | 0.12% | 144 |
|
|
2020
Q4 | $12.5M | Sell |
347,750
-14,989
| -4% | -$540K | 0.12% | 146 |
|
|
2020
Q3 | $13.9M | Sell |
362,739
-10,917
| -3% | -$421K | 0.15% | 121 |
|
|
2020
Q2 | $13.1M | Buy |
373,656
+14,380
| +4% | +$518K | 0.15% | 128 |
|
|
2020
Q1 | $11.7M | Sell |
359,276
-10,992
| -3% | -$429K | 0.16% | 118 |
|
|
2019
Q4 | $16.7M | Sell |
370,268
-8,811
| -2% | -$369K | 0.17% | 109 |
|
|
2019
Q3 | $15.4M | Sell |
379,079
-4,239
| -1% | -$180K | 0.17% | 112 |
|
|
2019
Q2 | $16.5M | Sell |
383,318
-10,647
| -3% | -$410K | 0.18% | 106 |
|
|
2019
Q1 | $15.1M | Sell |
393,965
-1,768
| -0.4% | -$67.5K | 0.16% | 113 |
|
|
2018
Q4 | $14M | Sell |
395,733
-6,560
| -2% | -$238K | 0.17% | 109 |
|
|
2018
Q3 | $15.5M | Sell |
402,293
-3,891
| -1% | -$136K | 0.16% | 118 |
|
|
2018
Q2 | $13.3M | Sell |
406,184
-7,580
| -2% | -$229K | 0.16% | 117 |
|
|
2018
Q1 | $11.3M | Sell |
413,764
-11,114
| -3% | -$302K | 0.13% | 148 |
|
|
2017
Q4 | $10.5M | Buy |
+424,878
| New | +$11.7M | 0.12% | 161 |
|
Other funds holding BSX
MetLife Investment Management's BSX Position: Q2 2026 in Review
MetLife Investment Management reduced its Boston Scientific (BSX) stake by 5% in Q2 2026, selling an estimated $972K and leaving 339,986 shares worth $14.5M. The position accounts for 0.07% of the portfolio, ranked #285.
MetLife Investment Management first reported a position in BSX in Q4 2017 and has held it in 35 quarters since. The position peaked at $41.7M in Q2 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- MetLife Investment Management held 339,986 shares of Boston Scientific worth $14.5M as of Q2 2026.
- MetLife Investment Management sold 17,908 Boston Scientific shares in Q2 2026, an estimated $972K.
- Boston Scientific made up 0.07% of MetLife Investment Management's portfolio in Q2 2026, its #285 holding.
- MetLife Investment Management first reported a position in Boston Scientific in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Boston Scientific position peaked at $41.7M in Q2 2025.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.